Deutsche Krebshilfe

Contents

Deutsche Krebshilfe is a major German nonprofit organization dedicated to cancer control, patient support, and medical research funding. Founded in 1974 by Mildred Scheel amid the healthcare debates of the 1970s, the organization has interacted with institutions such as the Bundestag, Federal Ministry of Health, and academic centers including the Charité – Universitätsmedizin Berlin, University of Heidelberg, and University of Munich. It operates nationally from its headquarters in Bonn and partners with international bodies like the Union for International Cancer Control and the European Cancer Organisation.

History

The organization was established in 1974 by Mildred Scheel following public campaigns and advocacy linked to figures such as Käte Strobel and policy discussions in the Bundestag. Early collaborations involved hospitals like Universitätsklinikum Bonn and research centers including the German Cancer Research Center (DKFZ) and universities such as Heidelberg University and Ludwig Maximilian University of Munich. During the 1980s and 1990s it expanded programmatically alongside initiatives from the World Health Organization and partnerships with foundations like the Robert Bosch Stiftung and the Max Planck Society. Its historical milestones include development of patient counseling networks modeled after patient advocacy examples like Medical Research Council initiatives and engagement with patient organizations such as Deutsche Krebsgesellschaft.

The organization’s stated mission emphasizes improving cancer prevention, early detection, treatment, and survivorship care, aligning with international objectives championed by the World Health Organization and the European Commission. Objectives include funding clinical research linked to institutions like the German Cancer Research Center and fostering multidisciplinary collaborations among centers such as the Charité – Universitätsmedizin Berlin and the University Medical Center Hamburg-Eppendorf. It aims to support patients in coordination with groups like Deutsche Krebsgesellschaft and healthcare providers in settings including the Robert Koch Institute surveillance frameworks and regional cancer registries in states such as North Rhine-Westphalia and Bavaria.

The governance model features boards and advisory councils resembling structures found at organizations such as the Deutsche Forschungsgemeinschaft and the Stifterverband für die Deutsche Wissenschaft. Leadership roles have been occupied by medical and public figures comparable to executives from the Robert Bosch Stiftung and academics affiliated with Heidelberg University and Charité – Universitätsmedizin Berlin. Funding streams combine private donations from citizens and corporate donors, endowments similar to those managed by the KfW development bank framework, and income from partnerships with pharmaceutical companies including multinational firms like Roche, Pfizer, and Novartis. Grantmaking practices reference models used by the European Research Council and philanthropic actors such as the Bill & Melinda Gates Foundation in terms of peer review and accountability.

Programs encompass patient counseling and navigation services that mirror practices at hospitals like Universitätsklinikum Freiburg and regional cancer centers such as the Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg. Activities include public information drives comparable to campaigns by the Deutsche Herzstiftung, funding for translational research projects with partners at the German Cancer Research Center and academic institutions like University of Tübingen and University of Cologne, and support for clinical trials in collaboration with networks such as the European Organisation for Research and Treatment of Cancer. The organization also sponsors training and continuing education for healthcare professionals, often in concert with professional societies such as the German Society for Hematology and Medical Oncology and the German Society for Radiation Oncology.

Grant programs prioritize basic science, translational projects, and clinical trials conducted at centers such as the German Cancer Research Center, Max Delbrück Center for Molecular Medicine, and university hospitals like Charité – Universitätsmedizin Berlin and University Hospital Essen. Funding mechanisms follow peer-review models used by the Deutsche Forschungsgemeinschaft and coordinate with EU frameworks such as Horizon 2020. Awards and fellowships have been granted to researchers affiliated with institutions including Heidelberg University, Ludwig Maximilian University of Munich, and the Technical University of Munich. The organization has supported registry and epidemiological studies in cooperation with the Robert Koch Institute and contributed to multicenter trials run through the German Cancer Consortium and international consortia like the European Cancer Patient Coalition.

Public campaigns stress secondary prevention and early detection, cooperating with state health ministries such as those of Baden-Württemberg and Hesse and national screening programs that intersect with initiatives from the Robert Koch Institute. Awareness drives often reference screening modalities and guidelines developed by professional bodies including the German Society for Gynecology and Obstetrics and the German Society for Gastroenterology, Digestive and Metabolic Diseases. Collaborations with media organizations and public figures mirror outreach efforts seen in campaigns by the Bundeszentrale für gesundheitliche Aufklärung and partner NGOs like Krebshilfe Landesverbände and patient advocacy groups such as European Cancer Patient Coalition.

The organization has been credited with strengthening cancer research capacity at institutions like the German Cancer Research Center and university hospitals including Charité – Universitätsmedizin Berlin and University Hospital Heidelberg, and with contributing to policy debates in the Bundestag and health ministries. Criticisms have focused on funding priorities and industry partnerships, echoing debates involving entities such as Transparency International and scrutiny similar to controversies around other funders like the Wellcome Trust and pharmaceutical collaborations with Pfizer and Roche. Academic and patient stakeholders from organizations such as Deutsche Krebsgesellschaft and the German Cancer Consortium have called for transparency measures and clearer metrics similar to reforms advocated by the Deutsche Forschungsgemeinschaft.

Category:Health charities in Germany Category:Cancer organizations